Shares of Turning Point Therapeutics (TPTX), a San Diego-based developer of targeted cancer drugs, soared 57% following the company’s initial public offering on Wednesday. Investors would do well to keep an eye on the firm, which could follow in the footsteps of companies such as Ignyta (sold to Roche for $1.7 billion in 2017) and Loxo Oncology (bought by Eli Lilly for $8 billion earlier this year).

Turning Point sold 9.25 million shares at a price of $18, the top of its pricing range, raising $166.5 million before underwriter discounts and commissions. The deal already valued the company at about $600 million before the stock popped to as high as $27 per share.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy